Their is certainly a need for additional funds in virtually any company that's in a similar developmental stage, and issuing more stock is always a possibility. The company has other possibilities as well, largely with licensing products for sale by other companies either on a regional basis, or worldwide. Any such agreement might be for a single product, or virtually everything they're developing. Such an agreement might bring in substantial funds, or perhaps would take over all trial costs, or could be anywhere in between. The point is, they could be working on many different options.
As I see the OWCP operation itself, it's a low cost operation. I believe all those working directly for the company do so on a part time basis, but I suspect that at times that might be well over 40 hours a week. I believe that many of them are compensated far more in stock than in salary.
I'm not suggesting that they'll continue to operate indefinitely in this manner, but growth in the company might not occur until product sales are actually generating revenue. It's also my belief that with their relationship with hospitals and others in Israel, they can conduct trials and do other research there rather inexpensively. The need for substantially greater funding will come as they get into larger Phase 2 and 3 Trials and especially when trials become multi-national and especially when the come to the U.S. I really don't know that this will happen before they have some sales revenue unless a partner is initiating and funding those trials.
I'm not saying they won't be fundraising in some way, they will, but they may not need nearly as much as we'd think while trials are small and being conducted in Israel.
Gary
